EUCTR2010-021253-39-SE进行中（未招募）不适用
Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open-label, multicentre phase II trial.
Swiss Group for Clinical Cancer Research SAKK0 个研究点目标入组 152 人开始时间: 2011年2月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 152
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Histologically confirmed FL CD20+; grade 1, 2, 3a; stage III+IV; stage II not suitable for radiotherapy
- •-Patients in need of systemic therapy: (at least one of these indications must be fulfilled)
- •symptomatic enlarged lymph nodes, spleen or other lymphoma manifestations
- •bulky disease = 6 cm in long diameter
- •clinically significant progression over at least 6 months of any tumor lesion
- •anemia (Hb < 100 g/L) or thrombocytopenia (Platelets < 100 x 109/L) due to lymphoma
- •clinically significant progressive decrease in Hb or platelet count due to lymphoma
- •B-symptoms ,weight loss > 10 % in 6 months, drenching night sweats or fever > 38°C not due to infection
- •-Patients must have at least one two-dimensionally measurable lesion with longest transverse diameter > 10 mm
- •-Paraffin embedded tumor tissue is available for sending for pathology review
- •-Age > 18 years
- •-WHO performance status 0-2
- •-For patients with history of cardiac disease or older than 70 years: adequate cardiac function must be confirmed by EF = 50%
- •-Adequate hematological values unless due to marrow infiltration by FL: (Neutrophils = 1.5 x 109/l, Platelets = 100 x 109/l)
- •-Adequate hepatic function: Bilirubin = 1.5 x ULN (unless due to Gilbert’s syndrome), ALT/AP = 2.5 x ULN
- •-Adequate renal function (calculated creatinine clearance = 30 ml/min, according to the formula of Cockroft-Gault)
- •-Patient must give written informed consent before randomization
- •-Patient compliance and geographic proximity allow proper staging and follow-up
- •-Women with Childbearing potential
- •are not pregnant and agree not to become pregnant during participation in the trial and during the 12 months thereafter
- •are using effective contraception since 30 days at least
- •have a negative pregnancy test within 4 days before randomization
- •-Men agree not to father a child, not to donate semen and to use condoms during trial treatment and 12 months thereafter
- •-Patients (male and female) agree to follow the special pregnancy prevention requirements for Revlimid® (lenalidomide)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •-Previous systemic therapy for follicular lymphoma
- •-Radiotherapy within the last 3 months
- •-Known CNS involvement
- •-Any serious underlying medical condition (at the judgment of the investigator) which could impair the ability of the patient to participate in the trial (e.g. active autoimmune disease, uncontrolled diabetes)
- •-Previous malignancy within 5 years with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer
- •-Psychiatric disorder precluding understanding information of trial related topics, giving informed consent, or interfering with compliance for oral drug intake
- •-Known hypersensitivity to trial drug(s) or hypersensitivity to any other component of the trial drugs
- •-Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information
- •-Concurrent treatment with other experimental drugs or other anti-cancer therapy, treatment in a clinical trial within 30 days prior to trial entry
- •-Known HIV+ infection or HCV infection
- •-Patients with any serological evidence of current or past hepatitis B, unless the serological findings are clearly due to vaccination
- •-Patients regularly taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to Prednisone = 15 mg/day for indications other than lymphoma or lymphoma-related symptoms
- •-Pregnant or lactating females
- •-Patients in need of urgent chemotherapy, e.g. because of existing or imminent compression
研究者
相似试验
进行中（未招募）
不适用
A comparison of two different treatments of patients with follicular lymphoma, i.e. the efficacy and tolerability of Rituximab in combination with a new drug (Revlimid) compared to the efficacy and tolerability of Rituximab alone .ntreated patients with follicular lymphoma in need of therapy.MedDRA version: 14.0Level: LLTClassification code 10059432Term: Follicular mixed small and large cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021253-39-FISwiss Group for Clinical Cancer Research SAKK152
进行中（未招募）
1 期
Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy.ntreated patients with follicular lymphoma in need of therapy.MedDRA version: 14.0Level: PTClassification code 10025310Term: LymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021253-39-DKSwiss Group for Clinical Cancer Research SAKK152
进行中（未招募）
1 期
Comparison of rituximab with lenalidomide or rituximab alone for patients with follicular lymphoma.EUCTR2010-021253-39-ITSAKK - GRUPPO SVIZZERO DI RICERCA CLINICA SUL CANCRO152
进行中（未招募）
1 期
Phase II study. A combination of Lenalidomide and Rituximab as front line therapy for elderly frail patients (CGA) with Diffuse Large B-cells non-Hodgkin Lymphoma.Diffuse Large B-cells non-Hodgkin LymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2015-003371-29-ITFONDAZIONE ITALIANA LINFOMI ONLUS68
进行中（未招募）
不适用
Rituximab plus Bendamustine as front line treatment in frail elderly (=70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi (FIL)EUCTR2011-001421-24-ITFONDAZIONE ITALIANA LINFOMI ONLUS